Nectin-4 TRAC

N/A

Report date: 2022/11/14 15:50:20

Base Information

Drug NameNectin-4 TRAC

Drug Alias NameToll-like Receptor Agonist Antibody Conjugate (TRAAC) comprised of a CpG oligodeoxynucleotide conjugated to a novel Nectin-4-targeting antibody for systemic administration and TME delivery of a potent TLR9 agonist.TAAC-001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionToll like receptor 9 agonistsAnti-NECTIN4

TargetsToll like receptor 9Nectin-4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTallac Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTallac Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A